Targeting Cancer Stem Cells to Revolutionize Cancer Therapies

Hear from 25 leading experts including:

- Dr Robert Weinberg, Founding Member, Whitehead Institute
- Dr Robert Hollingsworth, Director of Oncology, MedImmune
- Dr Bin-Bing Zhou, Senior Director, Oncology Discovery, Pfizer
- Dr Jan Van Tornout, Group Director, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb
- Dr Venkateshwar Reddy, Group Leader, Cancer Stem Cells, Novartis
- Dr Pradip Majumder, Scientist, Department of Oncology, Merck
- Dr Erica Jackson, Scientist and Research Group Leader, Genentech
- Dr Sonya Zabludoff, Associate Director, Cancer Bioscience, AstraZeneca
- Dr Mohamed Ragab, Global Partnering Head, Roche
- Dr Tom Okarma, Chief Executive Officer, Geron
- Dr Ivan Bergstein, Chief Executive Officer, Stemline Therapeutics
- Dr Manish Singh, Chief Executive Officer, ImmunoCellular Therapeutics
- Dr Thomas Davis, Associate Director, Oncology, PTC Therapeutics
- Dr Tim Hoey, Vice President, Cancer Biology, OncoMed
- Dr Paul Grayson, Chief Executive Officer, Fate Therapeutics
- Dr Raymond Winquist, Vice President, Vertex Pharmaceuticals
- Dr Patrick Baeuerle, Chief Scientific Officer, Micromet
- Dr Ram Mandalam, Chief Executive Officer, Cellerant Therapeutics
- Dr Agamemnon Epenetos, Chairman, Trojantec
- Dr Piyush Gupta, Researcher, Broad Institute
- Dr Brent Cochran, Principle Investigator, Tufts University
- Dr Stephen Gillies, Founder, President and Chief Executive Officer, Provenance Bio
- Dr Vito Palombella, Vice President, Drug Discovery, Infinity Pharmaceuticals
- Dr Jennie Mather, Senior Vice President, Stem Cell Research, MacroGenics

The world’s first and only meeting where you can hear the latest efforts to understand and target cancer stem cells from the leading companies in the field.

- Understand how the industry is using a growing understanding of cancer stem cells or tumor-initiating cells to dramatically improve cancer therapies, and what this will mean for your business and research.
- Meet all of the key cancer stem cells business and research leaders at the most influential big pharmaceutical and biotech companies operating in the field.
- Showcase your ideas and innovative research in front of the most influential cancer stem cells business leaders and scientists.
- Get the latest perspectives from the investment community on the cancer stem cells field, and learn how you can make your business and research more attractive to potential investors.
- Make the most of more dedicated networking time than any other industry event (including speed networking and scientific poster sessions) to discuss work and meet new clients or potential partners.

Register before January 29th and save $400
www.biorbis.com

Official Partners
Media Partners

To register: www.biorbis.com • Email at register@hansonwade.com
Tel at +44 (0) 203 141 8700 • Fax at +44 (0)20 7222 2685
Targeting Cancer Stem Cells to Revolutionize Cancer Therapies

The investigation and study of cancer stem cells represents an enormous opportunity for the pharmaceutical industry and has profound implications for cancer research and drug development.

Accelerating our understanding of CSC biology and successful development of CSC-targeting drugs will require a concerted effort from everyone in the field. Business leaders, research leaders and scientists all have a critical role to play, as do investors and technology suppliers.

This meeting will provide a platform for EVERYONE involved in CSC biology research and cancer drug development to accelerate progress in delivering more effective cancer drugs to patients.

• Find out how big pharma are capitalizing on the opportunity to develop better cancer drugs

• Listen to cancer stem cell biology experts as they outline the robust science that is underpinning the field

• Get the latest word from innovative biotech company leaders and scientists describing preclinical and clinical progress in designing targeted therapeutics

• Understand the role your research group or company can play in improving prospects for cancer patients

Don’t miss this opportunity to attend the world’s largest and best industry-focussed cancer stem cells event, meet the people accelerating the field and take your business and research to the next level.

Who is this meeting designed for?

This meeting is designed for scientists, research and business leaders, investors and business development executives at universities, research institutes, biotech/pharmaceutical companies and suppliers.

Whether you’re already involved in cancer research, or are looking for additional opportunities around existing programs in stem cell research or regenerative medicine, this event will provide you with the opportunity to meet the world’s most knowledgeable stakeholders in cancer stem cell research and drug development.

Make the Most of Your Time

A formal part of the agenda, our speed networking session offers attendees an opportunity to meet fellow delegates and speakers in a 60 minute period.

If you want to make the most of this meeting, don’t miss this session!
20 reasons why you need to attend

1. Meet and learn from big pharmaceutical and large biotech cancer stem cell research leaders and their teams. Take 10 big new ideas back to your organisation.

2. Network with the most influential people in the cancer stem cells field at the industry’s only global and commercially focussed cancer stem cells meeting.

3. Understand how every leading biotech in the field is targeting cancer stem cells by listening to, and meeting with, their business and research leaders. Learn what their latest efforts mean for your business.

4. Get the latest investor perspectives on cancer stem cells from big pharma, venture capital firms and investment banks, and learn how to increase the investment potential of your business and research.

5. Learn from Pfizer as Dr Bin-Bing Zhou, a Senior Director at Pfizer BioPharmaceuticals, outlines therapeutic strategies for targeting tumor-initiating cells.

6. Don’t just attend the meeting. Present your work to the industry at our poster session, and discuss your latest activities with the brightest minds in the field.

7. Listen to Medimmune describe how to identify and validate targets involved in CSC growth and development.

8. Determine mechanisms by which CSC-targeting agents are effective, in a session led by Dr Jan van Tornout of Bristol-Myers Squibb.

9. Genentech will describe how to characterize cells mediating resistance and relapse, using Non Small Cell Lung Cancer as a case study.

10. Assess the clinical evidence of telomerase inhibition in cancer patients first-hand, in a session led by Geron CEO Dr Thomas Okarma talking about Imetelstat.

11. Get the latest from Novartis as Dr Venkat Reddy outlines how they create novel assays for CSC target validation and testing therapeutic effect of candidates.

12. Understand the views of one of the field’s leading pioneers, Dr Robert Weinberg of the Whitehead Institute and MIT, on the role of cancer stem cells.

13. Have your say in developing a roadmap for overcoming barriers associated with CSC research in our interactive panel discussion.

14. OncoMed are perceived as the lead biotech by many in the CSC field. Listen to Dr Tim Hoey, their Vice President of Cancer Biology describe how they develop novel anti-cancer therapeutics.

15. Get a different perspective on treating cancer from Dr Paul Grayson, CEO of Fate Therapeutics, on cell transition in cancer and stem cell modulation.

16. Dr Sonya Zabludoff, Associate Director of Cancer Bioscience at AstraZeneca, describes important work on checkpoint kinases inhibitors, including updates on clinical trial results for AZD7762.

17. Several biotech companies have been pioneering the commercialization of CSC targeting therapies. Listen and learn from leaders at every important biotech in the space, including ImmunoCellular Therapeutics, Stemline Therapeutics, Micromet, Cellerant Therapeutic, Macrogenics and Trojantec.

18. Listen to Merck outline their latest work on GSI-mediated down-regulation of Notch signalling, including an overview of their research and development process.

19. Understand the views of Roche on the CSC field as Dr Mohamed Ragab, Global Partnering Head for Oncology, contributes on what needs to be demonstrated from an investment and partnering perspective.

20. This is the world’s only industry-focussed meeting on cancer stem cell therapeutic development and the only place where you can hear every leading biotech and big pharmaceutical company involved in the field. Don’t miss it!
SPONSORSHIP OPPORTUNITIES

13.00 Lunch and poster session

12.30
11.45
11.30
09.35
09.05
08.00

Meeting: 24th and 25th March 2010 | Venue: Le Meridien, Cambridge, MA | Website: www.biorbis.com

CONFERENCE DAY ONE: March 24th 2010

08.00 Registration, coffee and networking

09.00 Chairman’s opening remarks
Dr Raymond Winquist, Vice President, Vertex Pharmaceuticals

09.05 KEYNOTE ADDRESS: Addressing the role of cancer stem cells in tumour formation and progression

• Overview of the cancer stem cell theory and supporting evidence
• Implications of recent findings for the CSC model and future therapeutic approaches
Dr Robert A Weinberg, Founding Member, Whitehead Institute and Professor of Biology, MIT

ADVANCING CANCER STEM CELL RESEARCH

09.35 Case study: Targeting breast cancer stem cells and treatment resistance
• Revising the cancer stem cell concept
• Breast cancer stem cell biology
• Discovering agents that target drug resistant cancer subpopulations
Dr Piyush Gupta, Researcher, Broad Institute

10.05 Case study: The role of STAT 3 in glioblastoma stem cells
• STAT 3 and regulation of glioblastoma stem cell self renewal
• STAT 3 mediated regulation of key epigenetic modifiers in glioblastoma cells
• Understanding the implications for wider cancer stem cell research
Dr Brent Cochran, Principle Investigator, Tufts University School of Medicine

10.35 *** SPEED NETWORKING SESSION ***
Connect with speakers and other attendees early in the meeting and maximize the benefit of networking time

11.30 Morning refreshments

11.45 Novel approaches to Notch inhibition and p53/p21 replacement to destroy cancer stem cells
• Can cancer stem cell therapies avoid killing normal stem cells?
• What are preferred cancer stem cell therapies?
• Which cancer stem cell pathway should we be hitting?
• Do cancer stem cells use multiple cancer stem cell pathways to evade selective therapies?
Dr Agamemnon Epenetos, Chairman, Trojantec

12.30 PANEL DISCUSSION: Developing a roadmap for overcoming barriers associated with cancer stem cells research
• A discussion of roadblocks and critical rate limiting issues in cancer stem cell research
• Design of a roadmap: what needs to happen to overcome these barriers?
• How can we increase engagement with oncology leaders?
Dr Robert Weinberg, Founding Member, Whitehead Institute and Professor of Biology, MIT
Dr Brent Cochran, Principle Investigator, Tufts University School of Medicine
Dr Piyush Gupta, Researcher, Broad Institute
Dr Agamemnon Epenetos, Chairman, Trojantec

TRANSLATING RESEARCH INTO DRUG DEVELOPMENT I

14.00 Active Immunotherapy to target cancer stem cells (CSCs)
• CTLs can be generated against specific epitopes present on CSCs which have the ability to distinguish between normal and CSCs
• Clinical data from a phase I study in glioblastoma seems to provide significant clinical benefits with improved survival and progression
Dr Manish Singh, President and Chief Executive Officer, ImmunoCellular Therapeutics

14.30 Development of novel anti-cancer therapeutics that reduce tumor-initiating cell frequency
• The ability of tumor cells to propagate the disease is restricted to a sub-population that exhibit stem cell-like properties
• Development of antibodies that block signalling pathways essential for tumorigenesis mediated by cancer stem cells
• Anti-DLL4, an antibody with broad spectrum activity that blocks tumor growth through several mechanisms
Dr Tim Hoey, Vice President, Cancer Biology, OncoMed

15.00 Targeting post-transcriptional regulation of key stem cell proteins for cancer therapy: Bmi-1 as a case study
• The chemo-resistant fraction of tumor cells share many characteristics with stem cells
• Most stem cell-associated proteins, such as Bmi-1, are intractable by traditional drug discovery approaches
• Regulation by post-transcriptional mechanisms and use as a novel point of intervention
Dr Thomas Davis, Associate Director, Oncology, PTC Therapeutics

15.30 Imetelstat and the effect of telomerase inhibition on cancer stem/tumor-initiating cells
• Introduction to Imetelstat and the importance of telomerase inhibition in countering cancer stem cell activity
• Assessing the clinical evidence of telomerase inhibition in cancer patients
Dr Thomas Okarma, Chief Executive Officer, Geron

16.00 Afternoon refreshments

16.30 Developing clinical and pre-clinical drug candidates targeting cancer stem cells
• Clinical development of a drug candidate targeting CSCs
• Pre-clinical development of a pipeline of drug candidates targeting CSCs
• Discovery platform identification of CSC directed compounds
Dr Ivan Bergstein, Chief executive Officer, Stemline Therapeutics

17.00 Elimination of EpCAM-expressing CSCs by a T cell-engaging BiTE antibody
• BiTE antibodies and engagement of T cells for lysis of cancer cells: blinatumomab case study
• MT110, an EpCAM/CD3-bispecific BiTE antibody in phase I clinical trials
• Characterization of EpCAM, a target for MT110 that is a marker for CSCs
Dr Patrick Baeuerle, Chief Scientific Officer, Micromet

17.30 Development of antibody-based therapies targeting AML CSCs
• Identification of unique targets expressed on CSCs
• Development of in vitro assays and in vivo models
• Validation of targets and characterization of antibodies
Dr Ramkumar Mandalam, Chief Executive Officer, Cellerant Therapeutics

18.00 Chairman’s closing remarks

18.05 Poster session and networking
08.30 Registration, coffee and networking

09.00 Chairman’s opening remarks
Dr Raymond Winquist, Vice President, Vertex Pharmaceuticals

HOW INDUSTRY IS ADDRESSING CSC RESEARCH AND DRUG DEVELOPMENT

09.05 Targeting cancer stem cells: multiple myeloma as a model
• Complexities in elucidating mechanisms by which CSC-targeting agents are effective
• Preliminary data of a phase 1b trial in patients with multiple myeloma for a CSC targeted agent, a smoothened inhibitor
Dr Jan van Tornout, Group Director, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb

09.35 Characterization of the cells mediating resistance and relapse in Non Small Cell Lung Cancer
• Do tumors contain a specific population of chemoresistant cells?
• What are the unique properties of these cells?
Dr Erica Jackson, Senior Scientist, Genentech

10.05 Tumor-Initiating Cells: Challenges and opportunities for cancer drug discovery
• Therapeutic strategies targeting tumor-initiating cells
• Preclinical models integrating target validation, drug and biomarker discovery
Dr Bin-Bing Zhou, Senior Director, Oncology Discovery, Pfizer

10.35 Morning refreshments

11.05 In search of models and druggable targets in tumor-initiating cells
• Isolating and characterizing CSCs from a range of solid tumors and cancer cell lines
• Developing relevant self-renewal assays compatible with high throughput screening for functional genomic and small molecule screens
• Creating a new generation of in vitro assays for the validation of identified oncology targets with a focus on CSCs
• Developing in vivo efficacy models capable of interrogating the effect of therapeutics on CSCs
Dr Venkateshwar Reddy, Group Leader, Cancer Stem Cells, Novartis

11.35 GSI mediated down regulation of Notch signalling: Bench to bedside and back to bench
• Shedding light on tumor-initiating cells and their regulation by Notch signalling
• Taking research from the bench to the bedside and back again
Dr Pradip Majumder, Scientist, Department of Oncology, Merck

12.05 Discovery and early development of checkpoint kinase inhibitors
• Overview of checkpoint kinases as a CSC target
• Development of AZD7762, a potent ATP-competitive checkpoint kinase inhibitor in clinical trials
Dr Sonya Zabludoff, Associate Director, Cancer Bioscience, AstraZeneca

12.35 Lunch

13.35 Identification and validation of targets involved in CSC growth and survival, and biological drug development
• As assessment of CSC growth and survival
• Enhancing development of CSC-targeting biologics
Dr Robert Hollingsworth, Director of Oncology, MedImmune

INVESTING AND PARTNERING WITH CSC-FOCUSED BUSINESSES

14.05 PANEL DISCUSSION: Investor and partnering perspectives on CSCs: what needs to be demonstrated?
• Perspectives on the field of cancer stem cells
• What needs to be demonstrated by innovative biotechs to attract attention
Dr Mohamed Ragab, Global Partnering Head, Oncology, Roche
Jack Laserohn, General Partner, Vertical Group
Dr Keith Markey, Scientific Director, Griffin Securities

14.35 Afternoon refreshments

TRANSLATING RESEARCH INTO DRUG DEVELOPMENT II

14.55 Treating cancer: a stem cell company’s perspective
• What is the importance of developmental pathways and cell transition in cancer biology?
• How can stem cell modulation be applied to developing new chemotherapies?
Dr Paul Grayson, Chief Executive Officer, Fate Therapeutics

15.25 Generation of cancer stem cells and of monoclonal antibodies against target antigens
• Isolating cancer stem cells from primary tumors
• Identification of target antigens
• Monoclonal antibody development and preclinical results
Dr Jennie Mather, Senior Vice President, Stem Cell Research, MacroGenics

15.55 Clinical development of immunocytokines to target tumor-initiating (stem) cells
• Unique properties of this class of biologic supporting this approach
• Pre-clinical evidence for superiority over naked antibodies
• Early clinical signals
• DI-Leu16-IL2 for multiple clinical indications
Dr Stephen Gillies, Founder, President and Chief Executive Officer, Provenance Bio

16.25 Preclinical and clinical development of IPI-926, a novel Hedgehog pathway antagonist
• Understanding IPI-925, a novel inhibitor of the Hedgehog pathway
• Evaluation of IPI-926 in phase 1 clinical trials
• Examination of anti-tumor activity
Dr Vito Palombella, Vice President, Drug Discovery, Infinity Pharmaceuticals

16.55 Chairman’s closing remarks
Targeting Cancer Stem Cells

Meeting: 24th and 25th March 2010
Venue: Le Meridien, Cambridge, MA

HOW TO REGISTER

Online: www.biorbis.com
Tel: +44 (0)20 3141 8700
Email: register@hansonwade.com
Fax: +44 (0)20 7222 2685
Mail: Hanson Wade
Charter House
13 - 15 Carteret Street
London, United Kingdom
SW1H 9DJ

REGISTRATION FEES

<table>
<thead>
<tr>
<th>Book and pay by</th>
<th>Book and pay by</th>
<th>Standard Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 29th 2010*</td>
<td>February 19th 2010*</td>
<td></td>
</tr>
<tr>
<td>2 day meeting $1899</td>
<td>2 day meeting $2099</td>
<td>$2299</td>
</tr>
<tr>
<td>2 day meeting (not-for-profit organizations) $949</td>
<td>2 day meeting (not-for-profit organizations) $1049</td>
<td>$1149</td>
</tr>
</tbody>
</table>

CONFERENCE DOCUMENTATION $799

* To qualify for discounts payment must be received by the registration deadline. Early booking discounts are not valid in conjunction with any other offer.

TEAM DISCOUNTS

Book with a colleague and claim your discount:
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
* Please note that discounts are only valid when three or more delegates from one company book and pay at the same time

PURCHASE CONFERENCE DOCUMENTATION

If you are unable to attend, you may purchase the conference documentation for $799.
You will receive the documentation immediately after the conference. Documentation orders can only be processed on receipt of credit card details.

VENUE & ACCOMMODATION

Accommodation
Le Méridien Cambridge – MIT, Cambridge MA
20 Sidney Street
Cambridge
Massachusetts 02139
United States

We are currently negotiating the best rates at the conference hotel and will update our website with details. Please visit www.hansonwade.com/events/cancer-stem-cells

SPECIAL REQUIREMENTS

If you have any special dietary requirements or other needs that would enhance your enjoyment of this event, please contact us in advance and we will make every effort to assist you.

TERMS & CONDITIONS

Full payment is due on registration.
Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda:
Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection:
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes.
If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 83 Victoria Street, London, SW1H 0IW.
Tel: +44 203 141 8700.
Email: info@hansonwade.com

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216